Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 2 of 6

John Sinden, the chief scientific officer at stem-cell company ReNeuron says "we now have the justification to move into a proper randomised controlled trial because that’s what the field clearly needs."

John Sinden, chief scientific officer at stem-cell company ReNeuron, says that evidence of a treatment effect in the phase II trial justifies the move to a phase III trial, which is what the field needs

Source  ReNeuron